Breast Cancer Trial: First-Line Chemo-Immuno Combo Improves Outcomes

A large Phase III trial, the Impassion130 trial, has produced results supporting the use of chemotherapy plus immunotherapy as first-line treatment in certain patients with triple-negative breast cancer. The trial evaluated the combination of nab-paclitaxel, which is a chemotherapy drug, and atezolizumab, which is a checkpoint inhibitor. Together, the chemotherapeutic and the checkpoint inhibitor performed better than the chemotherapeutic alone. They increased both progression-free survival and